Mayzent

Siponimod, the active ingredient in Mayzent, is a sphingosine‑1‑phosphate (S1P) receptor modulator presented as an oral tablet for oral use. It treats relapsing forms of multiple sclerosis, including secondary progressive multiple sclerosis, in adults.

GNH USA supplies Mayzent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mayzent (siponimod) is used in the management of relapsing multiple sclerosis, a disease characterized by immune‑mediated central nervous system inflammation. - Relapsing‑remitting multiple sclerosis: reduces the frequency of clinical relapses and slows disability progression. - Secondary progressive multiple sclerosis with active disease: decreases relapse rate and may delay worsening of disability. - Active disease in adults with multiple sclerosis: limits new inflammatory lesions and improves MRI outcomes.

Siponimod may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Elevated liver enzymes: increase in ALT or AST observed in laboratory tests. - Hypertension: rise in blood pressure measured during routine monitoring.

Serious or Rare Side Effects: - Severe infections: opportunistic infections including fungal or viral pathogens. - Cardiac conduction abnormalities: bradycardia or atrioventricular block. - Macular edema: swelling of the central retina that may affect vision.

When prescribing siponimod, clinicians should consider several safety precautions. - Baseline cardiac assessment: perform ECG and monitor heart rate before initiating therapy. - Lymphocyte count monitoring: check absolute lymphocyte levels regularly to detect lymphopenia. - Liver function testing: assess ALT/AST at baseline and periodically during treatment. - Vaccination status: ensure patients are up‑to‑date with live vaccines before starting. - Pregnancy and breastfeeding: avoid use in pregnant or nursing women unless benefits outweigh risks. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Siponimod can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - CYP3A4 strong inhibitors: co‑administration may increase siponimod exposure and risk of toxicity. - CYP3A4 strong inducers: may reduce siponimod levels, decreasing therapeutic effect. - Live attenuated vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: siponimod may enhance blood‑pressure‑lowering effects. - Other immunosuppressants: combined use can increase infection risk. - QT‑prolonging drugs: monitor cardiac rhythm as additive effects are possible.